Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 518

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 518
---
 2024. TuHURA does not look to net income (loss) as a performance measure for its executive compensation program and instead looks at operational metrics, such as drug development milestones, pipeline progress, regulatory compliance, intellectual property, partnerships and collaborations, and general financial health of the company. 331

Policies and Practices Regarding Long-Term Incentive Awards

TuHURA’s compensation committee and senior management monitor TuHURA’s equity grant practices to evaluate whether such policies
comply with governing regulations and are consistent with good corporate practices. When making regular annual equity grants, the TuHURA compensation committee’s practice is to approve them at its meeting in January of each year as part of the
annual compensation review and after results for the preceding fiscal year become available. Because the TuHURA compensation committee’s regular meeting schedule is determined in the prior fiscal year, the proximity of any awards to other
significant corporate events is coincidental. In addition, the TuHURA compensation committee may make grants at any time during the year it deems appropriate, including with respect to new hires or transitions or for general retentive or incentive
needs. TuHURA attempts to make equity awards during periods when it does not have material non-public information (“MNPI”) that could impact TuHURA’s stock price and TuHURA’s does not time the release of MNPI based on equity
grant dates.

During 2024, no stock option grants were made to any of TuHURA’s named executive officers during any period beginning
four business days before the filing or furnishing of a periodic report or current report (other than a current report on Form 8-K disclosing a material new option award grant under Item 5.02(e) of that form) and ending one business day after the
filing or furnishing of any such report with the SEC.

Summary Description of the TuHURA Equity Plans

TuHURA (f/k/a Morphogenesis, Inc.) 2019 Amended and Restated Equity Incentive Plan

The TuHURA (f/k/a Morphogenesis, Inc.) 2019 Equity Incentive Plan (the “2019 Plan”) was approved by the TuHURA Board of Directors and
its stockholders in January 2019. The 2019 Plan, which amended and restated the TuHURA 2016 Stock Option Plan, provided for the issuance of up to 20,000,000 shares of TuHURA Common Stock, which includes the amount of outstanding